Tirzepatide is approved by the Food and Drug Administration (FDA) for treating type 2 diabetes and obesity, akin to other GLP ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

From singing on Broadway to playing beloved characters on the big screen (including everyone's favorite animated snowman, ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...